Awards and Recognition - The group was recognized with multiple awards, including the "CORPHUB Hong Kong Outstanding Leadership Award 2022" and the "BusinessFocus Business Award 2022" for its contributions to healthcare services and pandemic response[13]. - The company remains committed to providing high-quality healthcare services while actively participating in corporate social responsibility initiatives[13]. Healthcare Services and Network - The group is one of the largest and oldest listed healthcare groups in Hong Kong, emphasizing its dedication to health and life[13]. - The group has established one of the largest and most comprehensive primary healthcare service networks in Hong Kong, providing a wide range of services including general practice, specialist care, and dental services[15]. - The acquisition of Zhongzhu Medical, a private healthcare provider in Hong Kong, enhances the group's high-end specialist service capabilities and supports the development of medical tourism and cross-border healthcare[15]. - Nanyang Xiangrui's management of Nanshi Hospital continues to show organic growth, with revenue and net profit recording significant increases during the year[15]. - Nanshi Hospital's internet hospital services have served nearly 250,000 patients, expanding access to quality medical resources in Nanyang and surrounding areas[15]. - The group's health management business in mainland China focuses on enhancing quality and efficiency, with health check services remaining the largest revenue source[16]. - The Jinan International Health Management Center has successfully established a closed-loop system with corporate clients for health check services, contributing to revenue growth[16]. - The group plans to develop assisted reproductive services in collaboration with nearby hospitals and reproductive medicine centers in Guangzhou[16]. - The group's medical network management business in Hong Kong continues to grow despite challenges, with new doctors joining and the launch of a colorectal cancer screening program[35]. Financial Performance - The group recorded a consolidated profit of approximately HKD 49.52 million for the year, a decrease from HKD 75.07 million in the previous year, primarily due to losses from joint ventures and fair value losses on investment properties[43]. - The group reported a loss of approximately HKD 5.6 million from joint ventures, a shift from a profit of HKD 40.48 million in the previous year due to temporary closures of certain businesses amid the pandemic[43]. - The group recorded a fair value loss of approximately HKD 6.89 million on investment properties, compared to a fair value gain of HKD 47.65 million in the previous year, attributed to a contraction in the property market due to the pandemic[44]. - The company recorded revenue of approximately HKD 429.46 million in 2022, down from HKD 463.28 million in 2021, representing about 27.97% of the group's total revenue[104]. - Hong Kong medical services revenue reached approximately HKD 617.12 million, accounting for 40.19% of the group's total revenue, a significant increase from 31.70% in the previous year[106]. - The group successfully turned around its segment performance with a profit of approximately HKD 5.80 million, compared to a loss of HKD 12.93 million in the previous year[106]. COVID-19 Response - The group assisted in collecting over 3.4 million nucleic acid test samples and administered COVID-19 vaccines to nearly 120,000 individuals in mainland China during the year[38]. - The group administered over 2.3 million COVID-19 vaccine doses, representing approximately 11.41% of the total doses administered in Hong Kong[108]. - The group participated in managing multiple quarantine centers, providing round-the-clock medical support since March 2022[109]. - The group distributed hundreds of thousands of rapid antigen test kits to families of schoolchildren, supporting community health initiatives during the pandemic[111]. Business Development and Strategy - The company has expanded its health-related business with multiple brands, including "Xue Xian Shou" and "CO Health Care," covering major cities like Hong Kong, Shenzhen, Shanghai, and Guangzhou[64]. - The company is focusing on integrating all medical resources to create a comprehensive healthcare service ecosystem, addressing various healthcare needs from prevention to rehabilitation[65]. - The company has developed new IT modules to enhance internal management and improve data extraction, aiming for operational excellence[77]. - The company has established a joint venture for diversified testing services, including COVID-19 nucleic acid testing, to help identify hidden patients and prevent community transmission[82]. - The company is actively recruiting healthcare professionals and enhancing service experiences to prepare for post-pandemic challenges and opportunities[81]. - The company has acquired specialist brands to expand its market share in the local private healthcare sector, reinforcing its position[79]. - The company is leveraging big data and marketing strategies to drive growth in its beauty and health business segments[64]. - The company plans to consider investment and acquisition opportunities to enhance the healthcare service industry chain and integrate existing healthcare resources[94]. - The group aims to build a comprehensive, integrated, and one-stop cross-border healthcare service ecosystem to meet the diverse healthcare needs of over 86 million residents in the Greater Bay Area[94]. Human Resources and Financial Stability - The total employee cost for the year was approximately HKD 718,292,000, an increase from HKD 656,338,000 in 2021, representing a rise of about 9.4%[55]. - The group employed 1,395 staff as of December 31, 2022, up from 1,170 in 2021, marking an increase of approximately 19.3%[55]. - The group is committed to minimizing borrowing levels while maintaining sufficient resources to support business operations, which reflects a focus on financial stability[23]. - The group may consider additional fundraising activities when market conditions are favorable and opportunities arise[23]. Market Trends and Outlook - The company reported a significant increase in demand for healthcare services as the public health awareness rises, especially post-pandemic, indicating a positive outlook for the healthcare industry[65]. - The company is investing 50 million in R&D for new technologies aimed at enhancing user experience[5]. - Market expansion efforts have led to a 20% increase in market share in the Asia-Pacific region[6]. - The company provided a forward guidance of 10% revenue growth for the next quarter, projecting revenues between 1.3 billion and 3 billion, reflecting strong financial health[10].
康健国际医疗(03886) - 2022 - 年度财报